Efficacy and Immunogenicity Study of Recombinant Human Papillomavirus Bivalent（Type 16/18 ）Vaccine
A Phase III Multicenter, Randomized, Double-Blind, Placebo(Hepatitis E Vaccine)Controlled Study to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant(E.Coli)Human Papillomavirus Bivalent Vaccine in Healthy Women
Sponsor: Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
A PHASE3 clinical study on Cervical Cancer and Cervical Intraepithelial Neoplasia, this trial is completed. The trial is conducted by Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. and has accumulated 8 data snapshots since 2012. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Mar 2020 — Jan 2021 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jan 2020 — Mar 2020 [monthly]
Active Not Recruiting PHASE3
▶ Show 3 earlier versions
-
Aug 2018 — Jan 2020 [monthly]
Active Not Recruiting PHASE3
-
Jun 2018 — Aug 2018 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
First recorded
Nov 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
- Ministry of Science and Technology of the People´s Republic of China
- Xiamen Innovax Biotech Co., Ltd
- Xiamen University
For direct contact, visit the study record on ClinicalTrials.gov .